Effect of a single-dose denosumab on semen quality in infertile men (the FITMI study): study protocol for a randomized controlled trial

• Published in: Current controlled trials in cardiovascular medicine 2022-06, Vol.23 (1), p.525-525, Article 525
• Main Authors: Yahyavi, Sam Kafai, Holt, Rune, Juel Mortensen, Li, Petersen, Jørgen Holm, Jørgensen, Niels, Juul, Anders, Blomberg Jensen, Martin
• Format: Article
• Language: English
• Subjects: Apoptosis; Biomarkers; Care and treatment; Cell cycle; Clinical trials; Complications and side effects; Denosumab; Diabetes; Drug dosages; Hypocalcemia; Impaired semen quality; Infertility; Infertility, Male; Male infertility; Monoclonal antibodies; Osteoporosis; Patient outcomes; Randomized controlled study; Sperm; Study Protocol; Thyroid gland; Vitamin D; Vitamin deficiency
• ISSN: 1745-6215; 1745-6215
• DOI: 10.1186/s13063-022-06478-4

Background Infertility is a common problem globally and impaired semen quality is responsible for up to 40% of all cases. Almost all infertile couples are treated with either insemination or assisted reproductive techniques (ARTs) independent of the etiology of infertility because no medical treatment exists. Denosumab is an antibody that blocks RANKL signaling and inhibition of testicular RANKL signaling has been suggested to improve semen quality in a pilot study. This RCT aims to assess whether treatment with denosumab can improve spermatogenesis in infertile men selected by serum AMH as a positive predictive biomarker. This paper describes the design of the study. Methods/design FITMI is a sponsor-investigator-initiated, double-blinded, placebo-controlled 1:1, single-center, randomized clinical trial. Subjects will be randomized to receive either a single-dose denosumab 60 mg subcutaneous injection or placebo. The study will be carried out at the Department of Growth and Reproduction, Copenhagen University Hospital, Rigshospitalet, Copenhagen. The primary outcome of the study is defined as the difference in sperm concentration (millions pr. mL) one spermatogenesis (80 days) after inclusion. Discussion We describe a protocol for a planned RCT aimed at evaluating whether treatment with denosumab can improve the semen quality in infertile men selected by using serum AMH as a positive predictive biomarker. The results will provide evidence crucial for future treatment in a patient group where there is a huge unmet need. Trial registration Clinical Trials.gov NCT05212337. Registered on 14 January 2022. EudraCT 2021-003,451-42. Registered on 23 June 2021. Ethical committee H-21040145. Registered on 23 December 2021. Keywords: Denosumab, Male infertility, Impaired semen quality, Randomized controlled study